SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, has signed a contract with FedMed, Inc., one of the largest preferred provider organization networks in the United States, to provide access to bioTheranostics’ genomic tests for patients with breast cancer and metastatic cancers.
More than 40 million FedMed members nationwide can now benefit from bioTheranostics’ molecular diagnostic and predictive cancer tests, including the Breast Cancer IndexSM, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, and the bioT3 Metastatic Cancer Solution suite of tests, which provide diagnostic and therapeutic information for metastatic cancer patients at any stage across the continuum of care.
Help employers find you! Check out all the jobs and post your resume.
